Precision Medicine Approaches For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Precision Medicine Approaches for Neurodegeneration [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Therapeutic Strategy | [4]
| Approach | Genotype-guided, biomarker-stratified therapy | [5]
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, FTD | [6]
| Goal | Match therapies to individual patient characteristics | [7]
| Development Stage | Research to Early Clinical |
Precision medicine aims to tailor therapeutic interventions based on individual patient characteristics, including genetic background, biomarker profiles, disease subtype, and clinical presentation. In neurodegeneration, this approach seeks to overcome the high failure rate of clinical trials by stratifying patients and matching them to targeted therapies.
| Genetic Risk | Therapy Approach | Status |
|---|---|---|
| APOE ε4 carriers | Anti-amyloid, anti-tau immunotherapy | In trials |
| APP/PSEN1/PSEN2 mutations | Disease-modifying therapies | Research |
| TREM2 variants | TREM2 agonists, microglia modulators | Preclinical |
| Risk genes (CLU, PICALM) | Targeted approaches | Research |
| Genetic Risk | Therapy Approach | Status |
|---|---|---|
| LRRK2 G2019S | LRRK2 inhibitors | Phase II/III |
| GBA1 mutations | Enzyme enhancement, chaperones | Phase II |
| SNCA multiplications | Anti-α-synuclein therapies | Research |
| PARKIN, PINK1, DJ-1 | Mitochondrial protectors | Research |
| LRRK2 + GBA1 | Combination approaches | Research |
| Genetic Risk | Therapy Approach | Status |
|---|---|---|
| SOD1 mutations | ASO therapy (tofersen) | Approved |
| C9orf72 | ASO therapy | Phase I/II |
| FUS mutations | ASO therapy | Phase I |
| TARDBP | Targeting TDP-43 | Research |
| ALS2 | Gene therapy | Research |
| Genetic Feature | Therapy Approach | Status |
|---|---|---|
| HTT CAG repeat | ASO therapy (tominersen) | Phase III (failed) |
| CAG length | Treatment timing | Research |
| Genetic modifiers | Personalized approaches | Research |
| Biomarker Category | Markers | Clinical Use |
|---|---|---|
| A (Amyloid) | CSF Aβ42, PET | Patient selection |
| T (Tau) | CSF p-tau, PET | Staging, target engagement |
| N (Neurodegeneration) | FDG-PET, NfL, MRI | Disease progression |
Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) present significant stratification challenges due to:
| Biomarker | Test Method | Stratification Value | Clinical Action |
|---|---|---|---|
| p-tau217 | Plasma (SimOA) | Distinguish AD co-pathology vs primary 4R-tauopathy | Exclude from anti-tau if AD+; prioritize anti-amyloid if AD+ |
| NfL | Plasma/CSF | Progression rate prediction | Rapid progressors (NfL >60 pg/mL) need aggressive disease modification |
| GFAP | Plasma | Astrocytosis severity | Guide neuroinflammation-targeted therapy |
| MAPT genotype | Blood/WGS | 4R-tauopathy confirmation | Select for anti-tau therapies; exclude from anti-α-syn |
| Biomarker | Test Method | Stratification Value | Clinical Action |
|---|---|---|---|
| Tau PET | PET (PI-2620, PM-PBB3) | Regional tau burden | Enrich for anti-tau trials; confirm target engagement |
| DAT Scan | SPECT | Dopaminergic neuron loss | Confirm neurodegeneration; guide dopaminergic therapy |
| CSF total tau | Lumbar puncture | CBD vs PSP distinction | Inform prognosis |
| YKL-40 | CSF | Microglial activation | Select for CSF1R antagonists, JAK inhibitors |
| Gene | Variant | Frequency | Clinical Implication | Therapeutic Guidance |
|---|---|---|---|---|
| MAPT | H1/H1 homozygous | 95% PSP | Primary 4R-tauopathy | Anti-tau immunotherapy, ASOs |
| MAPT | p.R406W | Rare | CBS/PSP like | MAPT-targeted therapy |
| GBA1 | N370S, other | 5-10% | Gaucher disease carrier | Consider chaperone therapy (GZ/SAR402671) |
| LRRK2 | G2019S | 1-5% | Lewy body co-pathology | May respond to LRRK2 inhibitors |
| C9orf72 | Repeat expansion | <1% | ALS/FTD co-pathology | Monitor for motor neuron signs |
| TREM2 | R47H, R62H | 1-2% | Increased risk | May benefit from TREM2 agonists |
Priority interventions:
Avoid:
Priority interventions:
Consider:
Aggressive approach:
For the patient case (50yo male, suspected CBS/PSP, DAT scan confirmed dopamine loss):
| Factor | Value | Stratification Implication |
|---|---|---|
| Age | 50 | Relatively young — more aggressive therapy acceptable |
| Sex | Male | Standard dosing applies |
| DAT scan | Confirmed loss | Neurodegeneration confirmed |
| p-tau217 | Pending | Critical for AD co-pathology exclusion |
| NfL | Pending | Determines progression rate |
| Genetic panel | Pending | MAPT, GBA, LRRK2 status |
Initial recommendations pending biomarker results:
If p-tau217 negative (primary 4R-tauopathy):
If p-tau217 positive (AD co-pathology):
Regardless of p-tau217:
| Subtype | Characteristics | Targeted Approach |
|---|---|---|
| Typical AD | Amnestic, amyloid+/tau+ | Anti-amyloid/tau |
| Posterior cortical atrophy | Visual, occipital | Visual therapies |
| Logopenic PPA | Language, left temporal | Language-focused |
| Dysexecutive AD | Frontal | Executive function |
| Rapid progression | Fast decline | Aggressive therapy |
| Subtype | Characteristics | Targeted Approach |
|---|---|---|
| TD (Tremor-dominant) | Tremor, slow progression | Dopamine-sparing |
| PIGD (Postural instability) | Falls, rapid progression | Balance therapy |
| Cognitive | Early dementia | Dementia prevention |
| Mood/anxiety | Depression, anxiety | Mood-targeted |
| Gene | Drug | Effect | Clinical Use |
|---|---|---|---|
| CYP2D6 | Bromocriptine, pergolide | Metabolism variation | Dosing |
| COMT | Levodopa | Motor response | Prediction |
| APOE | Donepezil, immunotherapy | Response variation | Research |
| SCN1A | Carbamazepine (seizures) | Risk prediction | Contraindication |
| Design | Description | Advantages |
|---|---|---|
| Basket trials | Single therapy, multiple genotypes | Efficiency |
| Umbrella trials | Multiple therapies, single disease | Patient selection |
| N-of-1 trials | Individual patient optimization | Personalization |
| Adaptive trials | Interim analysis, modification | Flexibility |
| Disease | Therapy | Target | Companion Diagnostic |
|---|---|---|---|
| ALS (SOD1) | Tofersen (Qalsody) | SOD1 | Genetic testing |
| SMA | Nusinersen (Spinraza) | SMN2 | Genetic testing |
| Prion disease | Prion disease | PRNP | — |
The study of Precision Medicine Approaches For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schork NJ, et al. Precision medicine for Alzheimer's disease. Nature Reviews Neurology. 2019. ↩︎
Pagan F, et al. Precision medicine in Parkinson's disease. Movement Disorders. 2020. ↩︎
Benatar M, et al. ALS precision medicine. Neurology. 2020. ↩︎
Day J, et al. Genetic stratification in Huntington's disease. Brain. 2021. ↩︎
Miller T, et al. Trial of antisense oligonucleotides for SOD1-ALS. New England Journal of Medicine. 2020. ↩︎
Torkamani A, et al. Genomics and precision medicine. Cell. 2018. ↩︎
Frisanch O, et al. ATN framework for Alzheimer's disease. Lancet Neurology. 2018. ↩︎